GC Cell Corporation (KOSDAQ:144510)

South Korea flag South Korea · Delayed Price · Currency is KRW
25,300
+800 (3.27%)
At close: Feb 27, 2026
3.05%
Market Cap 380.19B
Revenue (ttm) 170.13B
Net Income (ttm) -98.19B
Shares Out 15.03M
EPS (ttm) -6,534.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,688
Average Volume 64,665
Open 25,700
Previous Close 24,500
Day's Range 24,800 - 25,800
52-Week Range 16,940 - 28,450
Beta 0.72
RSI 52.08
Earnings Date Feb 6, 2026

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 698
Stock Exchange KOSDAQ
Ticker Symbol 144510
Full Company Profile

Financial Performance

In 2024, GC Cell's revenue was 174.45 billion, a decrease of -6.98% compared to the previous year's 187.54 billion. Losses were -73.90 billion, 42368.9% more than in 2023.

Financial Statements

News

There is no news available yet.